Reassessing prognostic markers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors: the enduring value of body composition, nutritional, and inflammatory indices [0.03%]
免疫检查点抑制剂时代转移性肾细胞癌预后标志的再评估：体质组成、营养和炎症指标的持久价值
Norihiko Tsuchiya,Sei Naito,Hiroki Fukuhara et al.
Norihiko Tsuchiya et al.
Background: Immune checkpoint inhibitors (ICIs) are now the standard first-line treatment for metastatic renal cell carcinoma (mRCC), yet many risk factors identified during the tyrosine kinase inhibitor era remain unvali...
Pulmonary metastasectomy from bone and soft tissue sarcomas: defining surgical indications at the time of second pulmonary recurrence [0.03%]
骨和软组织肉瘤肺转移切除术：二程肺复发时的手术指征确定
Daichi Kakibuchi,Satoru Okada,Tatsuo Furuya et al.
Daichi Kakibuchi et al.
Background: Pulmonary metastasectomy (PM) is a treatment for lung metastases of bone and soft tissue sarcomas. However, the criteria for repeat PM after a second pulmonary recurrence remain unclear. We evaluated prognosti...
Genetic and molecular mechanisms in lung cancer with interstitial pneumonia [0.03%]
具有间质性肺炎的肺癌的遗传和分子机制
Aya Fukuizumi,Masahiro Seike
Aya Fukuizumi
Idiopathic pulmonary fibrosis (IPF) is associated with an increased risk of lung cancer, with cumulative incidence rates of 3.3% and 15.4% at 1 and 5 years of follow-up, respectively. The prognosis for patients with lung cancer and IPF is w...
Real-world clinical utility and challenges of comprehensive genomic profiling for advanced solid tumors in a community health institution [0.03%]
全面基因组测序在社区医疗机构中治疗晚期实体瘤的临床应用及挑战
Mihoko Doi,Nobuhisa Ishikawa,Katsunori Shinozaki et al.
Mihoko Doi et al.
Background: Comprehensive genomic profiling (CGP) tests were approved, and opportunities to consider tissue-agnostic targeted therapies based on molecular tumor profiling have increased even in the community-based medicin...
Clinical complete response and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy aimed at omission of surgery: an exploratory analysis of the JCOG1806 trial [0.03%]
新辅助化疗序贯手术的HER2阳性早期乳腺癌临床完全缓解及预测因素：JCOG1806研究探索性分析
Hideo Shigematsu,Tomomi Fujisawa,Fumikata Hara et al.
Hideo Shigematsu et al.
Purpose: The JCOG1806 trial (jRCTs031190129) is underway to evaluate the omission of surgery in patients with human epidermal growth factor receptor (HER2)-positive early breast cancer who have a clinical complete respons...
Peripheral blood lymphocyte and eosinophil dynamics with chemotherapy and pembrolizumab in cervical cancer [0.03%]
新辅助化疗联合派姆单抗治疗宫颈癌的外周血淋巴细胞和嗜酸性粒细胞动力学变化研究
Sho Sato,Masahiro Kagabu,Ami Jo et al.
Sho Sato et al.
Background: Cervical cancer poses a significant global health burden, particularly in its metastatic and recurrent forms, for which treatment options are limited. Although immune checkpoint inhibitors (ICIs) such as pembr...
Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma [0.03%]
EV-302/KEYNOTE-A39研究的泛亚组分析：评估恩沃单抗联合帕博利珠单抗用于既往未接受过治疗的晚期尿路上皮癌患者的III期临床试验
Eiji Kikuchi,Michiel S Van der Heijden,Begoña P Valderrama et al.
Eiji Kikuchi et al.
Background: In the phase 3 EV-302 study, enfortumab vedotin-pembrolizumab (EV + P) significantly prolonged overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with untreated locally a...
Molecular analysis of tumor recurrence using established cancer stem cell-line and drug discovery [0.03%]
基于癌干细胞系的肿瘤复发分子分析及其药物发现研究
Kiyotaka Nakano,Eiji Oki,Masaki Yamazaki et al.
Kiyotaka Nakano et al.
Despite advances in adjuvant therapy for colorectal cancer, tumor relapses, often driven by minimal residual disease, remain a formidable clinical challenge. The cancer stem cell hypothesis provides a key framework for understanding this pr...
Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatment [0.03%]
贝伐单抗联合单药化疗治疗携带BRCA突变铂耐药且在PARP抑制剂维持治疗期间复发的卵巢癌疗效及安全性分析
Eriko Takatori,Tadahiro Shoji,Ami Jo et al.
Eriko Takatori et al.
Background: Currently, there are no reports on the subsequent treatment of patients with ovarian cancer who exhibited platinum-resistant recurrence during treatment with poly (ADP-ribose) polymerase (PARP) inhibitors. Thi...
18F-PSMA-PET/CT in comparison with whole-body MRI and combination of conventional CT and bone scintigraphy for detection of recurrent disease in prostate cancer patients with rising PSA levels after initial definitive treatment [0.03%]
前列腺癌患者经初次根治性治疗后 PSA 水平升高时，18F-PSMA-PET/CT 与全身MRI和常规CT及骨扫描联合使用对复发性疾病的检测效果比较
Shiori Murata,Yusaku Moribata,Shusuke Akamatsu et al.
Shiori Murata et al.
Background: The purpose of this study was to compare the diagnostic performance of radiolabeled prostate-specific membrane antigen-targeted positron emission tomography/computed tomography (PSMA-PET/CT) with 18F, whole-bo...